Picture Name

Hello, welcome to the official website!

Contact Phone:400-000-0000

All

All
Product Management
News
Introduction
Enterprise outlets
FAQ
Enterprise Video
Enterprise Atlas

Search

Picture Name

Multi-language Jump
- 简体
- EN

News Center

2013

Release time：2013-01-01 10:41

The IND application of the Group's first project, GT0918 (Proxalutamide tablets), has been submitted for prostate cancer indications

Previous:

Next:

recommend News

2025-09-09

Completion Of Enrollment Of Subjects In Long-Term Human Safety Trial Of KT-939

2025-08-12

Phase II Clinical Trial Of GT20029 Gel For The Treatment Of Acne In China Reached Primary Endpoint

2025-07-31

Completion Of Patient Enrollment In Phase III Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China

2025-07-24

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult AGA In China Reached Primary Endpoint

2025-06-25

Receipt Of JNCI Designation For KT-939

2025-06-13

Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone

Find Us

图片名称

图片名称

WeChat

Copyright: Kintor Pharmaceutical Limited retains all copyrights.

SEO Business license Powered by 300.cn

Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn

Copyright: Kintor Pharmaceutical Limited retains all copyrights.

SEO Business license

Powered by 300.cn